Literature DB >> 22977273

Reference ranges and determinants of testosterone, dihydrotestosterone, and estradiol levels measured using liquid chromatography-tandem mass spectrometry in a population-based cohort of older men.

Bu B Yeap1, Helman Alfonso, S A Paul Chubb, David J Handelsman, Graeme J Hankey, Paul E Norman, Leon Flicker.   

Abstract

CONTEXT: Testosterone (T) levels decline with increasing age. Controversy exists over the threshold for classifying T as low vs. normal in older men. The relevance of assessing dihydrotestosterone (DHT) and estradiol (E2) remains unclear.
OBJECTIVE: We assessed the associations of T, DHT, and E2 in men aged 70 yr or older and established reference ranges for these in healthy older men. PARTICIPANTS: Community-dwelling men aged 70-89 yr residing in Perth, Western Australia, Australia, participated in the study. MAIN OUTCOME MEASURES: Plasma T, DHT, and E2 were assayed using liquid chromatography-tandem mass spectrometry in early morning samples from 3690 men.
RESULTS: Increasing age, higher body mass index and waist to hip ratio, dyslipidemia, diabetes, and higher LH were independently associated with lower levels of T and DHT. Increasing age, diabetes, and higher LH were associated with lower E2. In a reference group of 394 men aged 76.1 ± 3.2 yr reporting excellent or very good health with no history of smoking, diabetes, cardiovascular disease, cancer, depression, or dementia, the 2.5th percentile for T was 6.4 nmol/liter (184 ng/dl); DHT, 0.49 nmol/liter; and E2, 28 pmol/liter. Applying these cutoffs to all 3690 men, those with low T or DHT had an increased odds ratio for frailty, diabetes, and cardiovascular disease. Men with both low T and DHT had a higher odds ratio for these outcomes.
CONCLUSIONS: The 2.5th percentile in a reference group of healthy older men provides age-appropriate thresholds for defining low T, DHT, and E2. Additional studies are needed to test their potential applicability and clinical utility in older men.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22977273     DOI: 10.1210/jc.2012-2265

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  38 in total

1.  High variability in serum estradiol measurements in men and women.

Authors:  Hubert W Vesper; Julianne C Botelho; Meghan L Vidal; Yasamin Rahmani; Linda M Thienpont; Samuel P Caudill
Journal:  Steroids       Date:  2014-01-06       Impact factor: 2.668

Review 2.  Dihydrotestosterone: Biochemistry, Physiology, and Clinical Implications of Elevated Blood Levels.

Authors:  Ronald S Swerdloff; Robert E Dudley; Stephanie T Page; Christina Wang; Wael A Salameh
Journal:  Endocr Rev       Date:  2017-06-01       Impact factor: 19.871

Review 3.  Supraphysiologic-dose anabolic-androgenic steroid use: A risk factor for dementia?

Authors:  Marc J Kaufman; Gen Kanayama; James I Hudson; Harrison G Pope
Journal:  Neurosci Biobehav Rev       Date:  2019-02-25       Impact factor: 8.989

Review 4.  Aging and sex hormones in males.

Authors:  Maria Chiara Decaroli; Vincenzo Rochira
Journal:  Virulence       Date:  2016-11-10       Impact factor: 5.882

5.  Aging and estradiol effects on gene expression in the medial preoptic area, bed nucleus of the stria terminalis, and posterodorsal medial amygdala of male rats.

Authors:  Victoria L Nutsch; Margaret R Bell; Ryan G Will; Weiling Yin; Andrew Wolfe; Ross Gillette; Juan M Dominguez; Andrea C Gore
Journal:  Mol Cell Endocrinol       Date:  2016-12-20       Impact factor: 4.102

6.  Low testosterone is associated with disability in men with multiple sclerosis.

Authors:  R Bove; A Musallam; B C Healy; K Raghavan; B I Glanz; R Bakshi; H Weiner; P L De Jager; K K Miller; T Chitnis
Journal:  Mult Scler       Date:  2014-04-07       Impact factor: 6.312

7.  Revisiting hyper- and hypo-androgenism by tandem mass spectrometry.

Authors:  Flaminia Fanelli; Alessandra Gambineri; Marco Mezzullo; Valentina Vicennati; Carla Pelusi; Renato Pasquali; Uberto Pagotto
Journal:  Rev Endocr Metab Disord       Date:  2013-06       Impact factor: 6.514

Review 8.  Risks and benefits of testosterone therapy in older men.

Authors:  Matthew Spitzer; Grace Huang; Shehzad Basaria; Thomas G Travison; Shalender Bhasin
Journal:  Nat Rev Endocrinol       Date:  2013-04-16       Impact factor: 43.330

Review 9.  Challenges in Testosterone Measurement, Data Interpretation, and Methodological Appraisal of Interventional Trials.

Authors:  Landon W Trost; John P Mulhall
Journal:  J Sex Med       Date:  2016-05-18       Impact factor: 3.802

10.  Aging impairs VEGF-mediated, androgen-dependent regulation of angiogenesis.

Authors:  Laura Lecce; Yuen Ting Lam; Laura A Lindsay; Sui Ching Yuen; Philippa J L Simpson; David J Handelsman; Martin K C Ng
Journal:  Mol Endocrinol       Date:  2014-07-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.